Alexander Degelsegger-Márquez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alexander Degelsegger-Márquez has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Arnold Herzog
Austrian Medicines and Medical Devices Agency (AGES Medizinmarktaufsicht) Vienna Austria
2 shared publications - Bernd Jilma
Department of Clinical Pharmacology Medical University of Vienna Vienna Austria
2 shared publications - Bernhard Mraz
Gesellschaft für Pharmazeutische Medizin Vienna Austria
2 shared publications - Christa Wirthumer-Hoche
Austrian Medicines and Medical Devices Agency (AGES Medizinmarktaufsicht) Vienna Austria
2 shared publications - Claas Röhl
NF Kinder, Vienna, Austria
2 shared publications - Dejan Baltic
PHARMIG, Standing Committee Clinical Research
2 shared publications
Latest Publications
- Open Access
- 2 May 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26 (1) , e49910
IT-Related Barriers and Facilitators to the Implementation of a New European eHealth Solution, the Digital Survivorship Passport (SurPass Version 2.0): Semistructured Digital Survey
Background: To overcome knowledge gaps and optimize long-term follow-up (LTFU) care for childhood cancer survivors, the concept of the Survivorship Passport (SurPass) has been invented. Within the European PanCareSurPass project, the semiautomated and interoperable SurPass (version 2.0) will be optimized, implemented, and evaluated at 6 LTFU care centers representing 6 European countries and 3 distinct health system scenarios: (1) national electronic health information systems (EHISs) in Austria and Lithuania, (2) regional or local EHISs in Italy and Spain, and (3) cancer registries or hospital-based EHISs in Belgium and Germany. Objective: We aimed to identify and describe barriers and facilitators for SurPass (version 2.0) implementation concerning semiautomation of data input, interoperability, data protection, privacy, and cybersecurity. Methods: IT specialists from the 6 LTFU care centers participated in a semistructured digital survey focusing on IT-related barriers and facilitators to SurPass (version 2.0) implementation. We used the fit-viability model to assess the compatibility and feasibility of integrating SurPass into existing EHISs. Results: In total, 13/20 (65%) invited IT specialists participated. The main barriers and facilitators in all 3 health system scenarios related to semiautomated data input and interoperability included unaligned EHIS infrastructure and the use of interoperability frameworks and international coding systems. The main barriers and facilitators related to data protection or privacy and cybersecurity included pseudonymization of personal health data and data retention. According to the fit-viability model, the first health system scenario provides the best fit for SurPass implementation, followed by the second and third scenarios. Conclusions: This study provides essential insights into the information and IT-related influencing factors that need to be considered when implementing the SurPass (version 2.0) in clinical practice. We recommend the adoption of Health Level Seven Fast Healthcare Interoperability Resources and data security measures such as encryption, pseudonymization, and multifactor authentication to protect personal health data where applicable. In sum, this study offers practical insights into integrating digital health solutions into existing EHISs.
- 2 May 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26 (1) , e49910
Open AccessIT-Related Barriers and Facilitators to the Implementation of a New European eHealth Solution, the Digital Survivorship Passport (SurPass Version 2.0): Semistructured Digital Survey
Background: To overcome knowledge gaps and optimize long-term follow-up (LTFU) care for childhood cancer survivors, the concept of the Survivorship Passport (SurPass) has been invented. Within the European PanCareSurPass project, the semiautomated and interoperable SurPass (version 2.0) will be optimized, implemented, and evaluated at 6 LTFU care centers representing 6 European countries and 3 distinct health system scenarios: (1) national electronic health information systems (EHISs) in Austria and Lithuania, (2) regional or local EHISs in Italy and Spain, and (3) cancer registries or hospital-based EHISs in Belgium and Germany. Objective: We aimed to identify and describe barriers and facilitators for SurPass (version 2.0) implementation concerning semiautomation of data input, interoperability, data protection, privacy, and cybersecurity. Methods: IT specialists from the 6 LTFU care centers participated in a semistructured digital survey focusing on IT-related barriers and facilitators to SurPass (version 2.0) implementation. We used the fit-viability model to assess the compatibility and feasibility of integrating SurPass into existing EHISs. Results: In total, 13/20 (65%) invited IT specialists participated. The main barriers and facilitators in all 3 health system scenarios related to semiautomated data input and interoperability included unaligned EHIS infrastructure and the use of interoperability frameworks and international coding systems. The main barriers and facilitators related to data protection or privacy and cybersecurity included pseudonymization of personal health data and data retention. According to the fit-viability model, the first health system scenario provides the best fit for SurPass implementation, followed by the second and third scenarios. Conclusions: This study provides essential insights into the information and IT-related influencing factors that need to be considered when implementing the SurPass (version 2.0) in clinical practice. We recommend the adoption of Health Level Seven Fast Healthcare Interoperability Resources and data security measures such as encryption, pseudonymization, and multifactor authentication to protect personal health data where applicable. In sum, this study offers practical insights into integrating digital health solutions into existing EHISs.
- Open Access
- 17 June 2022
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 10 (6) , e34204
Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus
Real-world data (RWD) collected in routine health care processes and transformed to real-world evidence have become increasingly interesting within the research and medical communities to enhance medical research and support regulatory decision-making. Despite numerous European initiatives, there is still no cross-border consensus or guideline determining which qualities RWD must meet in order to be acceptable for decision-making within regulatory or routine clinical decision support. In the absence of guidelines defining the quality standards for RWD, an overview and first recommendations for quality criteria for RWD in pharmaceutical research and health care decision-making is needed in Austria. An Austrian multistakeholder expert group led by Gesellschaft für Pharmazeutische Medizin (Austrian Society for Pharmaceutical Medicine) met regularly; reviewed and discussed guidelines, frameworks, use cases, or viewpoints; and agreed unanimously on a set of quality criteria for RWD. This consensus statement was derived from the quality criteria for RWD to be used more effectively for medical research purposes beyond the registry-based studies discussed in the European Medicines Agency guideline for registry-based studies. This paper summarizes the recommendations for the quality criteria of RWD, which represents a minimum set of requirements. In order to future-proof registry-based studies, RWD should follow high-quality standards and be subjected to the quality assurance measures needed to underpin data quality. Furthermore, specific RWD quality aspects for individual use cases (eg, medical or pharmacoeconomic research), market authorization processes, or postmarket authorization phases have yet to be elaborated.
- 17 June 2022
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 10 (6) , e34204
Open AccessQuality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus
Real-world data (RWD) collected in routine health care processes and transformed to real-world evidence have become increasingly interesting within the research and medical communities to enhance medical research and support regulatory decision-making. Despite numerous European initiatives, there is still no cross-border consensus or guideline determining which qualities RWD must meet in order to be acceptable for decision-making within regulatory or routine clinical decision support. In the absence of guidelines defining the quality standards for RWD, an overview and first recommendations for quality criteria for RWD in pharmaceutical research and health care decision-making is needed in Austria. An Austrian multistakeholder expert group led by Gesellschaft für Pharmazeutische Medizin (Austrian Society for Pharmaceutical Medicine) met regularly; reviewed and discussed guidelines, frameworks, use cases, or viewpoints; and agreed unanimously on a set of quality criteria for RWD. This consensus statement was derived from the quality criteria for RWD to be used more effectively for medical research purposes beyond the registry-based studies discussed in the European Medicines Agency guideline for registry-based studies. This paper summarizes the recommendations for the quality criteria of RWD, which represents a minimum set of requirements. In order to future-proof registry-based studies, RWD should follow high-quality standards and be subjected to the quality assurance measures needed to underpin data quality. Furthermore, specific RWD quality aspects for individual use cases (eg, medical or pharmacoeconomic research), market authorization processes, or postmarket authorization phases have yet to be elaborated.
- Open Access
- 12 April 2022
- Published by Springer Nature in BioSocieties
- Vol. 18 (3) , 473-497
Value-creation in the health data domain: a typology of what health data help us do
It has become a trope to speak of the increasing value of health data in our societies. Such rhetoric is highly performative: it creates expectations, channels and justifies investments in data technologies and infrastructures, and portrays deliberations on political and legal issues as obstacles to the flow of data. Yet, important epistemic and political questions remain unexamined, such as how the value of data is created, what data journeys are envisioned by policies and regulation, and for whom data types are (intended to be) valuable. Drawing on two empirical cases, (a) interviews with physicians on the topic of digital selfcare, and (b) expectations of stakeholders on the use of Real-World Data in clinical trials, as well as existing literature, we propose a typology of what health data help us to do. This typology is intended to foster reflection about the different roles and values that data use unfolds. We conclude by discussing how regulation can better accommodate practices of valuation in the health data domain, with a particular focus on identifying regulatory challenges and opportunities for EU-level policy makers, and how Covid-19 has shed light on new aspects of each case.
- 12 April 2022
- Published by Springer Nature in BioSocieties
- Vol. 18 (3) , 473-497
Open AccessValue-creation in the health data domain: a typology of what health data help us do
It has become a trope to speak of the increasing value of health data in our societies. Such rhetoric is highly performative: it creates expectations, channels and justifies investments in data technologies and infrastructures, and portrays deliberations on political and legal issues as obstacles to the flow of data. Yet, important epistemic and political questions remain unexamined, such as how the value of data is created, what data journeys are envisioned by policies and regulation, and for whom data types are (intended to be) valuable. Drawing on two empirical cases, (a) interviews with physicians on the topic of digital selfcare, and (b) expectations of stakeholders on the use of Real-World Data in clinical trials, as well as existing literature, we propose a typology of what health data help us to do. This typology is intended to foster reflection about the different roles and values that data use unfolds. We conclude by discussing how regulation can better accommodate practices of valuation in the health data domain, with a particular focus on identifying regulatory challenges and opportunities for EU-level policy makers, and how Covid-19 has shed light on new aspects of each case.
- Open Access
- 11 October 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus (Preprint)
UNSTRUCTURED Real-world data (RWD) collected in routine health care processes and transformed to real-world evidence have become increasingly interesting within the research and medical communities to enhance medical research and support regulatory decision-making. Despite numerous European initiatives, there is still no cross-border consensus or guideline determining which qualities RWD must meet in order to be acceptable for decision-making within regulatory or routine clinical decision support. In the absence of guidelines defining the quality standards for RWD, an overview and first recommendations for quality criteria for RWD in pharmaceutical research and health care decision-making is needed in Austria. An Austrian multistakeholder expert group led by Gesellschaft für Pharmazeutische Medizin (Austrian Society for Pharmaceutical Medicine) met regularly; reviewed and discussed guidelines, frameworks, use cases, or viewpoints; and agreed unanimously on a set of quality criteria for RWD. This consensus statement was derived from the quality criteria for RWD to be used more effectively for medical research purposes beyond the registry-based studies discussed in the European Medicines Agency guideline for registry-based studies. This paper summarizes the recommendations for the quality criteria of RWD, which represents a minimum set of requirements. In order to future-proof registry-based studies, RWD should follow high-quality standards and be subjected to the quality assurance measures needed to underpin data quality. Furthermore, specific RWD quality aspects for individual use cases (eg, medical or pharmacoeconomic research), market authorization processes, or postmarket authorization phases have yet to be elaborated.
- 11 October 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessQuality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus (Preprint)
UNSTRUCTURED Real-world data (RWD) collected in routine health care processes and transformed to real-world evidence have become increasingly interesting within the research and medical communities to enhance medical research and support regulatory decision-making. Despite numerous European initiatives, there is still no cross-border consensus or guideline determining which qualities RWD must meet in order to be acceptable for decision-making within regulatory or routine clinical decision support. In the absence of guidelines defining the quality standards for RWD, an overview and first recommendations for quality criteria for RWD in pharmaceutical research and health care decision-making is needed in Austria. An Austrian multistakeholder expert group led by Gesellschaft für Pharmazeutische Medizin (Austrian Society for Pharmaceutical Medicine) met regularly; reviewed and discussed guidelines, frameworks, use cases, or viewpoints; and agreed unanimously on a set of quality criteria for RWD. This consensus statement was derived from the quality criteria for RWD to be used more effectively for medical research purposes beyond the registry-based studies discussed in the European Medicines Agency guideline for registry-based studies. This paper summarizes the recommendations for the quality criteria of RWD, which represents a minimum set of requirements. In order to future-proof registry-based studies, RWD should follow high-quality standards and be subjected to the quality assurance measures needed to underpin data quality. Furthermore, specific RWD quality aspects for individual use cases (eg, medical or pharmacoeconomic research), market authorization processes, or postmarket authorization phases have yet to be elaborated.
- Open Access
- 23 March 2021
- Published by Springer Nature
- p. 163-181
Tracing Technoscientific Collectives in Synthetic Biology: Interdisciplines and Communities of Knowledge Application
The relevance of collectives for scientific research has long been a matter of debate among sociologists of science and STS scholars. In this article, I revisit the notion of scientific communities from the perspective of practices in technoscientific fields of research. The case I focus on is synthetic biology, a field of research characterised by introducing engineering principles to biology. Drawing from field observations, a discussion of community concepts in sociological literature and interview data, I argue that concepts of community in the technosciences oversimplify the aspects and types of collectives that come to matter in research practices. The case of synthetic biology suggests that, when thinking about technoscientific communities, we have to consider aspects of research practices that point beyond knowledge production. To address this issue, I propose the notion of communities of knowledge application, which helps to reflect current trends in technoscientific research and research governance. Both contexts of knowledge production and contexts of knowledge application should be taken into account in an analysis of technoscientific communities.
- 23 March 2021
- Published by Springer Nature
- p. 163-181
Open AccessTracing Technoscientific Collectives in Synthetic Biology: Interdisciplines and Communities of Knowledge Application
The relevance of collectives for scientific research has long been a matter of debate among sociologists of science and STS scholars. In this article, I revisit the notion of scientific communities from the perspective of practices in technoscientific fields of research. The case I focus on is synthetic biology, a field of research characterised by introducing engineering principles to biology. Drawing from field observations, a discussion of community concepts in sociological literature and interview data, I argue that concepts of community in the technosciences oversimplify the aspects and types of collectives that come to matter in research practices. The case of synthetic biology suggests that, when thinking about technoscientific communities, we have to consider aspects of research practices that point beyond knowledge production. To address this issue, I propose the notion of communities of knowledge application, which helps to reflect current trends in technoscientific research and research governance. Both contexts of knowledge production and contexts of knowledge application should be taken into account in an analysis of technoscientific communities.
- Open Access
- 1 January 2020
- Published by IOS Press
- Vol. 271, 207-214
Medication Apps – A Systematic Search and Classification
The landscape of mobile health applications is evolving rapidly. This includes a growing set of medication-related health apps. Keeping track of the functional diversity in medication apps is a challenge for both practitioners and regulators, limiting the scope of innovative use of digital technologies in healthcare service delivery. In this paper, we present the results of a systematic search and functional classification of medication apps. We combine this with a discussion of the current and future landscape of regulation and reimbursement decision-making. We show that a majority of apps offers a cluster of functions including medication information, interaction checks and/or medication plans. The number of apps in the functional categories most affected by the Medical Device Regulation (identification, dosage, monitoring) is still low. This suggests that there is a window of opportunity for public sector decision-making on quality criteria.
- 1 January 2020
- Published by IOS Press
- Vol. 271, 207-214
Open AccessMedication Apps – A Systematic Search and Classification
The landscape of mobile health applications is evolving rapidly. This includes a growing set of medication-related health apps. Keeping track of the functional diversity in medication apps is a challenge for both practitioners and regulators, limiting the scope of innovative use of digital technologies in healthcare service delivery. In this paper, we present the results of a systematic search and functional classification of medication apps. We combine this with a discussion of the current and future landscape of regulation and reimbursement decision-making. We show that a majority of apps offers a cluster of functions including medication information, interaction checks and/or medication plans. The number of apps in the functional categories most affected by the Medical Device Regulation (identification, dosage, monitoring) is still low. This suggests that there is a window of opportunity for public sector decision-making on quality criteria.
- 20 August 2019
- Published by Taylor & Francis in Asia Pacific Business Review
- Vol. 25 (5) , 637-655
ASEAN’s science, technology and innovation policy: tension and integration between intergovernmentalism and sub-regional cooperation
In this paper, we research the role of the ASEAN level for science, technology and innovation (STI) in Southeast Asia. The key question is how the intergovernmental STI system relates to the diversity and traditional linkages in the region. Empirically, we address this question with data on STI inputs and outputs as well as qualitative evidence from interviews and participatory observation. We highlight a mismatch between national and intergovernmental dynamics in STI. Intra-ASEAN STI cooperation remains weak. We discuss multilateral research funding and increased cooperation in patent regimes as examples of new types of regional cooperation.
- 20 August 2019
- Published by Taylor & Francis in Asia Pacific Business Review
- Vol. 25 (5) , 637-655
ASEAN’s science, technology and innovation policy: tension and integration between intergovernmentalism and sub-regional cooperation
In this paper, we research the role of the ASEAN level for science, technology and innovation (STI) in Southeast Asia. The key question is how the intergovernmental STI system relates to the diversity and traditional linkages in the region. Empirically, we address this question with data on STI inputs and outputs as well as qualitative evidence from interviews and participatory observation. We highlight a mismatch between national and intergovernmental dynamics in STI. Intra-ASEAN STI cooperation remains weak. We discuss multilateral research funding and increased cooperation in patent regimes as examples of new types of regional cooperation.